Jeito Capital is a Paris-based independent venture capital firm dedicated to biopharma and biotech, financing and accelerating clinical-stage therapeutic innovation from development to market access. Founded in 2018 by Dr. Rafaèle Tordjman, it closed its second fund at $1.2 billion in 2025, the largest independent biopharma-focused raise in Europe.
50% of their portfolio is in Biotech & Life Sciences. Deal activity decreased year-over-year (1 deals in the last 12 months vs 10 prior). Their most common stage is series-b (40% of deals). Average disclosed round size is $124.2M (across 21 rounds with reported amounts).
Portfolio
34
Fund Size
$1.2B
Top Stage
Series B
Last 12 Mo
2
Team
Sabine Dandiguian
Managing Partner
Elaine Caughey
Partner, Business Development and Investor Relations
Magdalena Jonikas
Partner
Pascal Touchon
Operating Partner
Sarah Shackelton
Partner, Talent
Ana Leticia Maragno
Director of Translational science
Benjamin CAILLIER
Finance Director, Jeito Capital
Chloé Morlaàs
Investor Relations Director
Elsa Fernandez
Finance Director, Fund
Anastasiya Sybirna
Principal
Portfolio Breakdown
Stage Distribution
Sector Distribution
Investment Activity
Portfolio
| Company | Round | Amount | Date |
|---|---|---|---|
| PPrecirix | Series B | — | Aug 2026 |
| AAdcendo ApS | Series C | $75M | Apr 2026 |
 ReproNovo | Series A | $65M | May 2025 |
 Augustine Therapeutics | Series A | — | Mar 2025 |
 Callio Therapeutics | Series A | $187M | Mar 2025 |
 Xylocor | Series B | $67.5M | Jan 2025 |
| AAviceda Therapeutics | Series C | — | Jan 2025 |
 XyloCor Therapeutics | Series B | $67.5M | Jan 2025 |
 Noema Pharma | Series B | — | Dec 2024 |
 Alentis Therapeutics | Series D | $181.4M | Nov 2024 |
| AAlentis | Series D | $181.4M | Nov 2024 |
 CatalYm | Series D | $150M | Jul 2024 |
| HHI-Bio | Series B | $95M | Jan 2024 |
 Noema | Series B | — | Jan 2024 |
 NMD Pharma | Series B | — | Nov 2023 |
| Noema | Series B | — | Mar 2023 |
| NNoema Pharma AG | Series B | — | Mar 2023 |
| CCorteria | Series A | — | Jan 2023 |
| AAlentis | Series C | $105M | Jan 2023 |
 SparingVision | Series B | — | Sep 2022 |
 CDR-Life | Series A | $76M | Apr 2022 |
 PRECIRIX NV | Series B | — | Mar 2022 |
| NMD Pharma | Unknown | — | Feb 2022 |
 Quell Therapeutics | Series B | $156M | Nov 2021 |
| Quell Therapeutics | Series B | $156M | Jan 2021 |
Top Co-Investors
Last updated: 8 September 2026